Buserelin

SUPREFACT 1 mg/ml SOLUCION INYECTABLE

1,050 mg solución inyectableSpainMarketedAuthorised 31 May 1986

In other countries

The same active substances on other registers, the same brand first.

Suprefact DepotBrazil · Sanofi-Aventis Farmacêutica LtdaSame brand
SuprefactCanada · 1 MG / ML · Solution · Cheplapharm Arzneimittel GMBHSame brand
Suprefact Depot 2 MonthsCanada · 6.3 MG · Implant · Cheplapharm Arzneimittel GMBHSame brand
Suprefact Depot 3 MonthsCanada · 9.45 MG · Implant · Cheplapharm Arzneimittel GMBHSame brand
SuprefactItaly · Impianto · Cheplapharm Arzneimittel GMBHSame brand
Suprefact Depot 3 maanden, implantatiestift 9,45 mgNetherlands · Implantaat · Medcor Pharmaceuticals B.V.Same brand
Suprefact Depot 3 maanden, implantatiestift 9,45 mg

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Buserelin

SUPREFACT 1 mg/ml SOLUCION INYECTABLE

1,050 mg solución inyectableSpainMarketedAuthorised 31 May 1986

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Netherlands · Implantaat · CHEPLAPHARM Arzneimittel GmbH

AnyNew Zealand · Inj 1 mg per ml, 5.5 ml vial

Packs

Pack	Code	Status
SUPREFACT 1 mg/ml SOLUCION INYECTABLE , 2 viales de 5,5 ml	969626

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Buserelin
Strength: 1,050 mg
Dosage form: solución inyectable
Route: vía subcutánea
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 31 May 1986
Registration: 57011
Marketing authorisation holder: Cheplapharm Arzneimittel Gmbh
Procedure: National, MRP or DCP
Supply: Medicamento Sujeto A Prescripción Médica

Suspended

SUPREFACT DEPOT 6,3 mg IMPLANTE EN JERINGA PRECARGADABuserelin · 6,6 mg · implanteSpainSuspended